Effect of Prevnar 13 on Ear Infections in Children

Completed

Conditions studied: Otitis Media

In brief

Prevnar (7 valent pneumococcal conjugate vaccine \[7vPnC\]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.

Key facts

Study ID

NCT01199016

Run by

Pfizer

People needed

239

Starts

2010-09-01

Expected to finish

2016-01-01

Last updated by the study team

2017-03-01

Who can join

Age: 1 and older, up to 3. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has received full (3-dose) infant series of Prevnar 13

You may not qualify if…

• Prior vaccination with any 7vPnC.
• Prior vaccination with 23-valent pneumococcal polysaccharide vaccine (23vPS).
• Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in the study.

Where it is running

• Penfield Pediatrics — Penfield, New York, United States
• Long Pond Pediatrics — Rochester, New York, United States
• Legacy Pediatrics — Rochester, New York, United States
• Lewis Pediatrics — Rochester, New York, United States
• Pathway Pediatrics — Rochester, New York, United States
• Sunrise Pediatrics — Rochester, New York, United States
• Westfall Pediatrics — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.